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Abstract
Most valuation models begin with a measure of accounting earnings to arrive at cash flow
estimates. When using accounting earnings, we implicitly assume that the income is
obtained by netting out only those expenses that are operating expenses,  i.e., expenses
designed to generate revenues in the current period. Expenses that are intended to provide
benefits over multiple periods are assumed to be considered as capital expenditures, and
these expenses are depreciated or amortized over multiple periods. In addition, when
computing profitability measures such as return on equity and capital, we stick with this
assumption that operating income measures income generated by assets in place. In this
paper, we examine the accounting treatment of research and development expenses, and
the effects of the treatment on operating income, capital and profitability. We argue that
research and development expenses should be treated as tax-deductible capital
expenditures, for purposes of valuation, and this can have significant effects on operating
income, capital and expected growth measures for firms with substantial research
expenses.
The operating income for a firm is estimated by netting out all operating expenses
from revenues. When valuing a firm, we usually begin with after-tax operating income
and then reduce it by the reinvestment needs of the firm. The reinvestment needs cover
any investments that the firm needs to make to generate future growth, and include both
capital expenditures and working capital investments. The distinction between operating
and capital expenditures is critical for tax calculations, and is important in determining
both the amount of capital on a firm's books and how its profitability is measured.
In this paper, we will consider the accounting treatment of research and
development expenses as operating expenses, and argue that it is not appropriate to do so,
at least for valuation purposes.  Considering research and development expenses as
capital expenses will have profound effects on estimates of cash flow and growth in
valuation, and in determining earnings multiples for purposes of relative valuation.
Operating and Capital Expenditures
Accounting statements classify all expenses into three categories - operating
expenses, financing expenses and capital expenses. Operating expenses are expenses that,
at least in theory, provide benefits only for the current period; the cost of labor and
materials expended to create products which are sold in the current period would be a
good example. Financing expenses are expenses arising from the non-equity financing
used to raise capital for the business; the most common example is interest expenses.
Capital expenses are expenses that are expected to generate benefits over multiple
periods; for instance, the cost of buying land and buildings is treated as a capital expense.
Operating expenses are subtracted from revenues in the current period to arrive at a
measure of operating earnings from the firm. Financing expenses are subtracted from
operating earnings to estimate earnings to equity investors or net income. Capital
expenses are written off over their useful life (in terms of generating benefits) as
depreciation or amortization.
The distinction between operating and financing expenses may not be significant
for tax purposes, since both are tax deductible, but the distinction between operating and
capital expenses affects taxes. Operating expenses are deductible in the period in which
they are made, whereas capital expenses are written off over the useful life of the
investment. The distinction also matters for purposes of asset and capital measurement.
Operating expenses create no assets and affect capital only indirectly through retained
earnings. Capital expenses, on the other hand, create assets and consequently affect
capital as well.
The Accounting Treatment of Research and Development Expenses
Capital expenditures are defined as those expenditures that are likely to create
benefits over multiple periods. By this definition, investments in land, plant and long
term equipment are capital investments, but so is research and development. In fact, a
reasonable argument can be made that research and development expenses (R&D) are
more long term than investments in physical plant and equipment at many firms,
especially those in the pharmaceutical and high technology sectors. Thus, it follows that
R&D expenses should be treated as capital expenditures. In reality, however, accounting
standards in the United States require the treatment of R&D as operating expenses. In this
section, we will examine the consequences of this rule for earnings and capital
measurement at firms with substantial research expenses.
Accounting Rules Governing R&D Expenses
Prior to 1975, companies in the United States were allowed to capitalize R&D
expenses. Accounting rule SFAS 2, which has governed the treatment of research and
development expenses since 1975, requires that all R&D expenses be expensed in the
period incurred. The only exception is for contract R&D done for unrelated entities.
The rationale for treating forcing firms to expense R&D seems to lie in the belief
that the benefits are uncertain, and occur only when the research leads to a commercial
product. Consequently, it is argued that the asset created by research is not one that can
be used by the firm to borrow money. This, to us, sounds like a dangerous path to follow.
Using this reasoning, there are a number of capital investments, especially those in riskier
businesses, which would qualify for expensing, simply because they have no liquidation
value and have uncertain cash flows.
Outside the United States, IAS 9 also requires the expensing of research cost but
allows for the capitalization of development expenses. Development costs are defined to
include all costs involved in turning research into commercial products or services. In the
UK and Canada, firms are permitted, but not required, to capitalize development costs as
the research gets closer to commercial exploitation. In general, though, most companies
in most countries expense research and development expenses.
Consequences for Earnings Measurement
The treatment of R&D as an operating expense has the immediate effect of
lowering both operating and net income. The tax deductibility of these expenses buffers
the impact somewhat, and the net income and after-tax operating income are both
reduced by the following:
After-tax Effect of R&D expense on earnings = R&D Expenses (1 - marginal tax rate)
For companies that end up with negative earnings as a consequence of research expenses,
the after-tax effect will be even larger because the tax benefit has to be deferred until
future periods.
The treatment of research expenditures as operating expenses also implies that
research expenditures create no assets. Thus, patents that emerge from internal research
will not be shown as assets on the balance sheet. In contrast, patents acquired from third
parties can be treated as assets. This contradiction in the treatment of patents has given
rise to game playing on the part of firms with substantial research expenditures
R&D Partnerships
In an R&D partnership, a group of investors creates a partnership, which agrees to
cover the entire research and development expense for a firm. In return, the partnership
gets the rights to any products developed by the partnership. In most cases, however, the
firm preserves the right to purchase the partnership or license the product some time in
the future. From the perspective of the firm, this arrangement essentially means that R&D
expenses are eliminated, because the revenues from the partnership cover the expenses
entirely. For partners in the partnership, there is the potential at least of a large payoff if
the research pays off in the form of commercial products.
This arrangement can clearly be misused by firms that want to move research
expenses off the books, and borrow funds to finance this research. SFAS 68 requires that
there be an actual transfer of risk from the firm to the partnership. In other words, the
firm should not be under any obligation to return cash received from the partnership, if
the research does not pay off.
A Financial Analysis of Research and Development Expenses
Research and development expenses are designed to generate future growth and
should be treated as capital expenditures. In this section, we will consider how to
reclassify research expenses and the consequences for reported earnings, capital and
profitability.
A Reclassification of R&D Expenses
The first step in the reclassification of R&D expenses is to remove it from
operating expenses and show it as a capital expenditure. The steps that follow are not as
simple. First, the reclassified R&D expense becomes a capital expense and is no longer
expensed. Second, capital expenses create assets, and R&D is not an exception. The
after-tax R&D expense has to be cumulated over time to create an asset that we can
loosely call the research asset.  Third, like other assets, the research asset can lose value
over time and hence may have to be amortized over its life.  The amortization that is
generated is not tax deductible, but it will affect operating income.
The movement of R&D from the operating expense to the capital expenditure
column can have profound implications for profitability measures and for projections of
cash flows into the future.
The Effect on Assets and Capital
When we treat R&D expenses as capital expenditures, we have to maintain
consistency and treat cumulated R&D expenses as an asset. The simplest way to do this is
to cumulate the after-tax research and development expenses1 over time and create a
research asset. This asset will then be amortized over time, with both the length of the
amortization period and the amortization schedule being determined by the nature of the
research expenses, and the estimated time until there is a payoff to the investment. Thus,
for pharmaceutical companies where FDA approval can take as long as a decade, the
research asset will be amortized over an extended period. In contrast, for high technology
firms where the payoff is much sooner, the research asset will have to be amortized over
a shorter period.
                                                
1 The reason we cumulate after-tax  research and development expenses is because R&D expenses are tax
deductible. Amortizing the entire R&D expense will generate amortization that is too large, relative to the
capital investment from R&D.
If the research is on clearly identified products, there is a more direct approach to
amortization. Research expenses should be completely written off when one of two
scenarios occur. One is if the product is found not to be viable, and is abandoned. The
research expense on that product should then be written off. The other is if the firm
decides to invest in producing the product commercially, in which case the research
expense on the asset has to be written off and replaced with the physical assets created by
the investment.
The capital and assets of a firm will increase when R&D expenses are capitalized,
but the extent of the change will depend upon how long the company has been in
existence and its cumulated R&D over that period. Thus, firms which have been in
existence for a long period and have invested substantially in R&D over that period will
see a much bigger change in their capital than firms that have been around for short
period. The amortization schedule can also make a difference, since the cumulated
research asset gets reduced by the amortization each year. Thus, the research asset for a
firm that amortizes its research over five years, can be estimated by cumulating R&D
expenses over the last five years2 and reducing this cumulated amount by the
amortization on these expenses.
                                                
2 There might have been R&D expenses prior to the five years, but they will have no material impact on the
current value of the research asset since they would have been entirely amortized by now.
Is there a way to estimate the market value of the research asset? The value of the
patents generated by the research can be estimated using real option models, but basic
research will be difficult to value.
Illustration 1: Effect on Capital and Equity of Reclassifying R& D Expenses: Boeing
To value the research asset for Boeing, we first need to make an assumption about
the amortizable life of the research asset. In the case of Boeing, the products are new and
improved airplanes that have long commercial lives. Consequently, we use a ten-year life
for Boeing’s research asset, and assume that any research expenses are amortized
uniformally in the ten years after the expense is incurred.  The following table values the
research asset at Boeing, based upon the R&D expenses at Boeing over the last 10 years
(including the current year):
Year R&D Unamortized PortionUnamortized Value
1988 $751 0.10 $75
1989 $754 0.20 $151
1990 $827 0.30 $248
1991 $1,417 0.40 $567
1992 $1,846 0.50 $923
1993 $1,661 0.60 $997
1994 $1,704 0.70 $1,193
1995 $1,300 0.80 $1,040
1996 $1,633 0.90 $1,470
1997 $1,924 1.00 $1,924
Capitalized Value of R& D Expenses = $8,587
Note that with the assumption of straight line amortization, only 1/10th of the research
expense in 1988 remains amortized, 2/10th of the expense in 1989 and so on The value of
the research asset at Boeing is a substantial $8.587 billion.
This research asset augments the assets , equity and capital of the firm. Thus, the
adjusted book value of aasets, equity and capital at Boeing can be estimated as follows:
Equity Capital
Book Value $14,353 $22,319
 + Research Asset $8,587 $8,587
 = Adjusted Book Value $21,540 $30,907
Firms with significant research expenditures will have much higher values for assets,
capital and equity once research expenditures are capitalized.
The Effect on Operating and Net Income
Will treating research and development expenses as capital expenditures increase
or decrease operating income? The effect depends upon the trend in research
expenditures and amortization of previous research expenses. To illustrate, the following
table lays out operating income, with the conventional treatment of R&D expenses, and
operating income, with R&D treated as a capital expenditure:






= Operating Income after taxes
Revenues
- Operating Expenses
- Amortization of Research Asset
= Operating Income
- Taxes (based on conventional treatment)
= Operating Income after taxes
Whether operating income increases or decreases when R&D is reclassified will depend
upon whether the amortization of the research asset is greater than or less than the R&D
expense in the current year. For high growth firms, where R&D expenses tend to grow
substantially over time, the reclassification will lead to an increase in operating income.
As these firms mature, and R&D expenses level off, the operating income may well
decrease.
Illustration 2: Effect of R&D Reclassification on Operating and Net Income
In the following analysis, we will examine the effects of reclassifying R&D
expenses as capital expenditures on operating income and net income at Boeing.
Operating Income $1,078
 + Research and Development Expenses $1,924
 - Amortization of Research Asset $1,272
 = Adjusted Operating Income $1,731
We also compute the effect on after-tax operating income of capitalizing  R&D  expenses
as capital expenditures.
Operating Income (1-t) $701
 + Research and Development Expenses $1,924
 - Amortization of Research Asset $1,272
 = Adjusted After-tax  Operating Income $1,353
Note that this estimate of the after-tax operating income is different from that obtained by
multiplying the adjusted operating income by (1- tax rate). This reflects the tax benefit
earned by the firm because the revenue code allows the entire R&D expense to be
deducted for tax purposes, unlike its treatment of other capital  expenditures. The
magnitude of the tax benefit to the firm from expensing R&D, as opposed to capitalizing
it, can be computed as follows:
Adjusted After-tax Operating Income = $ 1,353 million
Adjusted Operating Income (1- tax rate)= $ 1,125 million
Tax Benefit = $    208 million
Finally, we look at the effect on net income of reclassifying research and
development expenses as capital expenditures.
Net Income $721
 + R & D expenses $1,924
 - Amortization of Research Asset $1,272
 = Adjusted Net Income $1,384
Again, the adjusted net income reflects the tax benefit created by the tax treatment of
research and development expenditures.
The Effects on Profitability
The reclassification of R&D from an operating to a capital expense has a
significant impact on both the earnings and the capital estimates for a firm. Thus, the
return on equity and capital for  a firm will change when the reclassification is made.
Will the return on equity and capital increase or decrease when R&D is recategorized?
The return on capital after the recategorization of R&D will look as follows:
ROCR&D Adjusted=
EBIT(1-t)+R&D Expense   - Amortization of Research Asset 
(BV of Capital + Research Asset) 
The effect of reclassifying R&D expenses will depend upon two factors:
- The magnitude of the R&D expense is in the current year relative to R&D expenses
in prior years: When the current R&D expense is significantly higher than expenses
in previous years the returns on equity and capital will increase on the
recategorization. (The increase in operating income in proportional terms will be
greater than the increase in capital invested). When the current R&D expense is
similar to or smaller than R&D expenses in previous years, the returns on equity and
capital will drop when R&D expenses are recategorized.
- The level of the unadjusted return on capital:  Firms with high unadjusted returns on
capital are much more likely to see drops in the return when research and
development is classified as a capital expenditure. This is because the net research
expense (After-tax R&D expense - R&D amortization) as a percent of the research
asset is likely to be lower than the unadjusted return on capital and thus pull the
return down.
The effects on return on equity are similar, though the effects will be magnified
because the proportional impact on net income and book value of equity of reclassifying
R&D expenses is likely to be larger.
Illustration 3: Effects of R&D Reclassification on Profitability Measures
To compute the effects of reclassifying research and development expenses on
profitability measures, we first compute the return on capital using both adjusted and
unadjusted measures of operating income and capital:
Boeing Boeing (Adjusted)
After-tax Operating Income $701 $1,353
BV of Capital - Beginning $21,547 $30,039
BV of Capital - Ending $20,363 $30,907
BV of Capital - Average $20,955 $30,473
ROC (based on average) 3.34% 4.44%
ROC (based on beginning) 3.25% 4.51%
Note that the both beginning and ending capital are increased by the assessed value of the
research asset. The net effect of reclassifying R&D expenses is an increase in the return
on capital.
The effect on return on equity can also be similarly assessed. To do so, we
compute the adjusted net income and book value of equity:
Return Ratios  Boeing  Boeing
(Adjusted)
Net Income $732 $1,384
BV of Equity- Beginning $13,502 $21,437
BV of Equity- Ending $12,953 $22,940
BV of Equity - Average $13,228 $22,188
ROE (based on average) 5.53% 6.24%
ROE (based on beginning) 5.42% 6.46%
Note again that the return on equity increases when net income and book value of equity
are adjusted to reflect the recapitalization of R&D expenses.
The Effect on Cash Flows
Reclassifying R&D expenses as capital expenses does not affect current cash
flows since it has no tax effect. The following table clearly indicates this:
Cash Flow with Conventional Treatment of
R&D






+ R& D Expense
- R & D Amortization
- Change in Working Capital
= Free Cash Flow to Firm
= Adjusted After-tax Operating Income
+ R & D Amortization
+ Depreciation
- Cap Ex
- R & D Expense
- Change in Working Capital
= Free Cash Flow to Firm
Note that the taxes are still based upon the unadjusted operating income, and that
reclassifying R&D for analysis purposes does not affect tax calculations. Working
through the expanded calculation, we arrive at the same free cash flow to the firm. The
same analysis applies when we look at free cash flow to equity.
If there is no effect on the free cash flows, why bother with the reclassification in
the first place? By separating out R&D expenses from other operating expenses, we get a
cleaner picture of what a firm is actually earning on its assets in place, and how much it is
investing for future growth. This becomes critical when we project these cash flows into
the future.
The Effects on Expected Growth
The real effects of recategorizing R&D show up when we compute the expected
growth in operating income and cash flows. Note that the growth in operating income can
be written in terms of the reinvestment rate and the return on capital earned on
investments.
GrowthEBIT = Reinvestment Rate * Return on Capital
Where,
Reinvestment Rate = (Cap Ex - Depreciation + Change in Working Capital)/ EBIT (1-t)
Return on Capital = EBIT (1-t) / Capital Invested
Firms whose primary capital expenditures are research and development expenses
often have anemic reinvestment rates, when R&D is classified as an operating expense
and thus look like they should have really low expected growth rates. The return on
capital is also misestimated for the same reasons.
When R&D is reclassified as a capital expenditure, the reinvestment rate and
return on capital will be affected:
Reinvestment RateR&D Adjusted=
Cap Ex - Depreciation + D W C + R&D Expense - Amortization of Research Asset  
EBIT(1-t ) + R&D Expense - Amortization of Research Asset  
ROCR&D Adjusted=
EBIT(1-t)+R&D Expense  - Amortization of Research Asset 
(BV of Capital + Research Asset) 
The growth in operating income will then reflect these changes. Generally, rapidly
growing firms that increase research expenditures proportionately will have much higher
reinvestment rates and lower return on capital after the adjustment. This will then result
in higher growth in operating income.
The reclassification of research expenses also allows us to discriminate between
growth firms that are investing in research and growth firms that are not. When R&D
expenses are treated as operating expenses, the latter will look much better on all
measures of profitability from operating margins to returns on capital. Treating R&D
expenses as capital expenditures allows us to bring both groups of firms to an equal
footing in terms of profitability measures, while giving firms that are investing in
research the benefits of higher growth and potentially higher value.
Illustration 4: Effects on Reinvestment Rate and Expected Growth
In the following table, we compute the reinvestment rate, return on capital and
expected growth rate for Boeing using unadjusted numbers and estimates adjusted to
reflect the capitalization of research expenses:
UnadjustedWith R&D capitalized
Net Cap Ex $37 $689
EBIT(1-t) $701 $1,353
Reinvestment Rate 5.28% 50.94%
Return on Capital 3.25% 4.51%
Expected Growth 0.17% 2.29%
Note that the reinvestment rate increases dramatically when we count the research
expenses as capital expenditures. This reflects the fact the research expenses at Boeing
have been increasing over time.
The Effect on Discounted Cash Flow Value
While reclassifying R&D expenses as capital expenditures might have no effect
on current cash flows, it has profound effects on valuation for the following reasons:
- The estimates of expected growth can be tied much more closely to whether and how
much a firm is investing for that growth (in R&D) and how effective it is in
converting the R&D into profits (through the return on capital). Thus, it forces
analysts to consider not just the magnitude of research expenditures but the quality of
these investments as well.
- In valuation we often assume that operating margins and returns on capital at firms
converge on industry averages as we move through time. If these industry averages
are computed using the conventional definition of R&D as an operating expense,
there is no reason to assume that firms will move towards these averages. If, on the
other hand, the industry averages are computed with R&D reclassified as a capital
expenditure, it can be argued that competitive pressures will push margins towards
convergence.
- When computing terminal value, it is critical that assumptions about growth be
consistent with assumptions about reinvestment rates and returns on capital. This is
impossible to do as long as R&D expenses are treated as operating expenses. When
they are reclassified as capital expenditures, the reinvestment rate can be computed
and it will include research and development expenses.
Illustration 5: Effects of R& D Reclassification on Value
In the following illustration, we value Boeing twice, once with the conventional
treatment of R&D as an expense and once with R&D expenses capitalized. We first
present the valuation of Boeing, using the reported after-tax operating income. We begin
by applying the fundamental growth rate (from the reinvestment rate and return on capital
estimated in illustration 4) to revenues. Since 1997 was a year in which Boeing reported
significantly lower operating income than in prior year, we projected that the after-tax
operating margin would recover to the average level that Boeing enjoyed between 1992
and 1996. The improvement to the “target” margin of 4.12% is assumed to occur linearly
from the current level over the next 3 years. After year 3, we assume that the company is
in stable growth.
For the other components, we assume that capital expenditures and depreciation
grow at the same rate as revenues, and that non-cash working capital remains 5% of
revenues over the entire period.
Base 1 2 3 Terminal Year
Revenues $45,800 $45,879 $45,957 $46,036 $46,115
Operating Margin 1.53% 2.39% 3.26% 4.12% 4.12%
EBIT(1-t) $701 $1,098 $1,497 $1,898 $1,901
 + Deprec’n & Amort. 1354  $        1,356  $        1,359  $        1,361  $        1,363
 - Capital Exp -1391  $      (1,393)  $      (1,396)  $      (1,398)  $      (1,401)
 - Change in WC  $               4  $               4  $               4  $               4
FCFF $1,057 $1,456 $1,856 $1,860
Terminal Value  $      20,529
Present Value  $           968  $        1,221  $      17,177
Value of Firm =  $      19,365
Growth Rate in Revenues = 0.17%
Target after-tax Operating Margin = 4.12%
Working Capital as % of Revenues = 5%
Cost of Capital = 9.23%
The growth rate used is computed based upon the reinvestment rate and return on capital
computed in illustration 4.
We also valued Boeing, with R&D expenses re-categorized as capital expenses.
This affects every aspect of the valuation:
- The operating income used is the adjusted operating income estimated in illustration
2, with R&D expenses capitalized and amortized.
- The target after-tax operating margin in stable growth is the pre-R&D margin
estimated for Boeing to be 5.55%, instead of 4.12%.
- The depreciation is augmented by the amortization of R&D expenses over time. We
assume that both the R&D expenses and the amortization increase at the revenue
growth rate over this period.
- The capital expenditures include the estimated R&D expenses over time
The following table summarizes the valuation of Boeing with these inputs:
Base 1 2 3 Terminal Year
Revenues $45,800.00  $ 46,850.98  $ 47,926.08  $ 49,025.85  $ 50,150.85
Operating Margin 2.95% 3.82% 4.68% 5.55% 5.55%
EBIT(1-t) $1,353  $   1,788.99  $   2,244.02  $   2,718.99  $   2,781.38
 + Deprec'n & Amort $2,626  $        2,686  $        2,748  $        2,811  $        2,875
 - Capital Exp ($3,315)  $      (3,391)  $      (3,469)  $      (3,548)  $      (3,630)
 - Change in WC  $             53  $             54  $             55  $             56
FCFF  $        1,031  $        1,469  $        1,926  $        1,970
Terminal Value  $      28,410
Present Value  $           944  $        1,231  $      23,278
Value of Firm  $      25,453
Growth Rate in Revenues = 2.29%
Target after-tax Operating Margin 5.55%
Working Capital as % of Revenues 5%
Cost of Capital = 9.23%
Note that the expected growth rate of 2.29% in revenues is estimated based upon the
adjusted reinvestment rate and return on capital for Boeing. Overall, the value of Boeing
as a firm increases by about $ 6 billion.
The effects on valuation of capitalizing R&D expenses tend to be greatest when
the growth rate is computed from the reinvestment rate and the return on capital. When
the growth rate is an exogenous variable, analysts often adjust the growth rate to reflect
the opportunities created by research. In these cases, the effects on value tend to be
unpredictable, and value can be much higher than or lower than the true value, depending
upon whether the growth rate is over or under estimated.
The Effects on Earnings Multiples
When research and development expenses are reclassified, there will be
significant shifts in some of the multiples commonly used in valuation. All earnings
multiples will have to be re-estimated, since reclassifying R&D as a capital expenditure
changes both operating income and net income. Thus, price-earnings ratios, PEG ratios,
Value/EBIT and Value/EBITDA multiples will all be affected. The book value ratios will
also change since the book value of capital and equity will both shift when R&D is
reclassified as an asset.
To the extent that multiples are used to compare how companies within a sector
are valued, there are some who argue that there should be no change in the relative
valuations and rankings when R&D is reclassified. This is clearly not true since R&D
expenses vary across companies, depending upon their relative size, growth and stage in
the life cycle. As a general rule, the earnings multiples of smaller, higher growth
companies will decrease relative to the earnings multiples of larger, more mature firms.
Illustration 6: Effects of R& D Reclassification on Multiples
In the following table, we summarize both earnings and book value multiples for
Boeing, when R&D expenses are capitalized, and compare them to the conventional
measures:
Unadjusted Adjusted
PE Ratio            36.75           23.55
Value/EBITDA            16.83             9.40
Price/Book Value of Equity              2.52             1.51
Value/ Book Value of Capital             1.83             1.32
Note that the adjustment reduces the PE ratio, because the net income is much higher
when R&D expenses are capitalized for Boeing. This reflects the fact that Boeing
research expenses have been increasing over time, and the expense thus outweighs the
amortization charge. There is a similar effect on the Value/EBITDA multiple, but this
effect will occur for all firms with research expenses, since the amortization of the
expense is added back.
Finally, the addition of the research asset to the book value of equity and capital
reduces the market to book ratios for all firms with research expenses, though the
magnitude of the impact will vary depending upon how large the expenses are relative to
the size of the firm.
Conclusion
Accounting rules clearly specify that operating expenses are expenses
designed to generate income in the current period, whereas capital expenditures are
designed to provide benefits over multiple periods. The current treatment of research and
development expenses are operating expenses seems to violate this distinction. In this
paper, we have argued that R&D expenses are in fact capital expenditures and should
therefore not be shown as part of operating expenses. To be consistent, we also argue that
research and development expenses create a research asset that has to be amortized over
time.
The effects of reclassifying R&D expenses on operating income and profitability
ratios will vary across companies. In firms where R&D expenses have been increasing
rapidly over time, reclassifying R&D can push up operating income significantly and can
make return on capital a much higher number. In mature firms, where R&D expenses
have been stable over time, the return on capital may decrease when R&D is reclassified.
